Ventyx Biosciences Inc Earnings

The next earnings date for Ventyx Biosciences Inc is March 19, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Ventyx Biosciences Inc Earnings

Report DateEstimated Earnings Per Share
05/07/2026$-0.41
03/19/2026$-0.37

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Ventyx Biosciences Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
11/07/2025---$-0.3228.89%
08/07/2025---$-0.3817.39%
06/05/2025After Market$-0.3943.48%
02/28/2025---$-0.4124.87%
11/04/2024After Market$-0.503.85%
08/09/2024---$-0.4521.64%
05/09/2024After Market$-0.6210.14%
02/27/2024After Market$-0.7912.22%
11/09/2023After Market$-0.92-2.22%
08/10/2023After Market$-0.91-28.17%
05/11/2023After Market$-0.68-4.62%
03/23/2023After Market$-0.623.13%
11/03/2022After Market$-0.59-34.09%
08/15/2022After Market$-0.3913.33%
05/12/2022After Market$-0.4513.46%
03/23/2022Before Market$-0.3664.00%
11/17/2021After Market$-3.17-780.56%
06/30/2021---$-0.92---
03/31/2021---$-0.92---
06/30/2020---$-0.12---
03/31/2020---$-0.12---

More About Ventyx Biosciences Inc

Country
USA
Full Time Employees
83

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Ventyx Biosciences Inc Earnings” Can Refer to the Ventyx Biosciences Inc Earnings Date

Some people say “Ventyx Biosciences Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Ventyx Biosciences Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Ventyx Biosciences Inc Stock on the Earnings Date

If you own Ventyx Biosciences Inc stock (VTYX) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Ventyx Biosciences Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Ventyx Biosciences Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Ventyx Biosciences Inc Earnings

You can contact us any time if you would like to ask questions about Ventyx Biosciences Inc earnings or anything else related to the stock market.